Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Benign Hepatobiliary Disease
  • Biliary Tract Cancer
  • Cholangiocarcinoma
  • Gallbladder Cancer
  • Healthy, no Evidence of Disease
  • Hepatocellular Carcinoma
  • Liver Cancer
  • Precancerous Condition
Type
Observational
Design
Observational Model: CohortTime Perspective: Prospective

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

OBJECTIVES: Observe the biomarkers of resectable hepatobiliary tumor recurrence (DFS) and survival (OS); Observe the evolution of tumors and discover specific diagnostic markers as a control group. Observe the response (ORR), progression (PFS) and survival (OS) biomarkers of targeted immunotherapy f...

OBJECTIVES: Observe the biomarkers of resectable hepatobiliary tumor recurrence (DFS) and survival (OS); Observe the evolution of tumors and discover specific diagnostic markers as a control group. Observe the response (ORR), progression (PFS) and survival (OS) biomarkers of targeted immunotherapy for advanced hepatobiliary tumors; To elaborate on the multi-omics study of hepatobiliary tumors, to further subtype and find therapeutic targets

Tracking Information

NCT #
NCT04445532
Collaborators
  • OrigiMed
  • GeneCast Biotechnology Co., Ltd.
  • YuceBio Technology Co., Ltd.
Investigators
Principal Investigator: Haitao Zhao, MD Peking Union Medical College Hospital